Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients

Figure 3

Number of IFN-γ producing cells when incubated overnight with prostate cancer cell line PC-3 in PBMC collected at baseline (preimmunotherapy [preIT]), during infusions (post inf#), and postimmunotherapy (1 week postimmunotherapy [1W postIT], 1 month postimmunotherapy [1 M postIT], and one year postimmunotherapy [1Y postIT]). (a) Increased number of IFN-γ producing cells during infusions and postIT time points in a partial responder (FG60163) when PBMC were incubated with prostate cancer specific PC-3 targets. (b) and (c) Enhanced IFN-γ responses in minor responders (FG60202 and FG91760).

(a)

(b)

(c)